Sulfacetamide
Blephamide, Cetapred, Fml-s, Gyne-sulf, Klaron, Metimyd, Predamide, Predsulfair, Sulphrin, Sulster, Sultrin, Trysul, Vagilia, Vasocidin (sulfacetamide) is a small molecule pharmaceutical. Sulfacetamide was first approved as Blephamide on 1982-01-01. It is used to treat bacterial infections, bacterial skin diseases, corneal ulcer, ear diseases, and seborrheic dermatitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Klaron (generic drugs available since 1982-01-01, discontinued: Bleph, Cetamide, Isopto cetamide, Ocusulf, Sulamyd, Sulf, Sulfacel, Sulfair, Sulten)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluorometholone
+
Sulfacetamide sodium
Prednisolone acetate
+
Sulfacetamide sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BLEPHAMIDE | Allergan | N-012813 DISCN | 1982-01-01 | 1 products, RLD |
| METIMYD | Merck Sharp & Dohme | N-010210 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Prednisolone sodium phosphate
+
Sulfacetamide sodium
Sulfacetamide sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KLARON | Bausch Health Companies | N-019931 RX | 1996-12-23 | 1 products, RLD, RS |
Show 1 discontinued
Sulfacetamide
+
Sulfathiazole)
+
Triple sulfa (sulfabenzamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SULTRIN | Johnson & Johnson | N-005794 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clindamycin 1% / sodium sulfacetamide monohydrate 5% / tretinoin 0.025% | unapproved drug other | 2019-05-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bacterial infections | — | D001424 | A49 |
| bacterial skin diseases | — | D017192 | — |
| corneal ulcer | — | D003320 | H16.0 |
| ear diseases | EFO_1001455 | D004427 | H93.9 |
| seborrheic dermatitis | — | D012628 | L21 |
| trachoma | — | D014141 | A71 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF06: Sulfacetamide
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AB: Sulfonamides, ophthalmologic antiinfectives
— S01AB04: Sulfacetamide
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meibomian gland dysfunction | D000080343 | — | H02.88 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Neoplastic processes | D009385 | — | — | — | — | — | — | 1 | 1 |
| Pathologic processes | D010335 | — | — | — | — | — | — | 1 | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sulfacetamide |
| INN | sulfacetamide |
| Description | Sulfacetamide is a sulfonamide that is sulfanilamide acylated on the sulfonamide nitrogen. It has a role as an antimicrobial agent, an antiinfective agent, an EC 2.5.1.15 (dihydropteroate synthase) inhibitor and an antibacterial drug. It is a substituted aniline and a N-sulfonylcarboxamide. It is functionally related to a sulfanilamide. It is a conjugate acid of a sulfacetamide(1-). |
| Classification | Small molecule |
| Drug class | antimicrobials (sulfonamides derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NS(=O)(=O)c1ccc(N)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 144-80-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL455 |
| ChEBI ID | 63845 |
| PubChem CID | 5320 |
| DrugBank | DB00634 |
| UNII ID | 4965G3J0F5 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,273 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
648 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use